3D-PCT Combined With CT-guided Radioactive I-125 Seed Implantation in the Treatment of Head and Neck Tumors

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2026

Conditions
Malignant Tumor of Head and/or Neck
Interventions
RADIATION

Radioactive Iodine-125 Seeds Implantation

Radioactive Iodine-125 Seeds Implantation(RISI) belongs to permanent inter-tissue brachytherapy. Guided by CT or ultrasound,radioactive I-125 seeds are implanted into tumor tissue, and radioactive I-125 continuously releases radiation to kill tumor cells.Radioactive I-125 seeds can reach a higher dose in the tumor, and the dose of the normal tissue around the tumor is lower, and the damage to the normal tissue is less while reaching the radical dose. The NCCN guidelines recommend RISI as the standard treatment for early prostate cancer. For early prostate cancer, RISI can achieve comparable efficacy as surgery, complications and side effects are lower than surgery, therefore patients can obtain better quality of life. RISI is also recommended by NCCN as one of the treatments for locally recurrent rectal cancer. Several studies have confirmed that RISI is safe and effective in the treatment of locally advanced or recurrent head and neck, chest, abdominal and retroperitoneal tumors.

Trial Locations (1)

Unknown

RECRUITING

Department of Radiation Oncology of Peking university third hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER